



Review

Post-Transcriptional Modification by Alternative Splicing and Pathogenic Splicing Variants in Cardiovascular Development and Congenital Heart Defects

Zubin Mehta^{1,2,3,4} and Marlin Touma^{1,2,3,4,*} 

- ¹ Neonatal/Congenital Heart Laboratory, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
 - ² Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
 - ³ Children's Discovery and Innovation Institute, Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
 - ⁴ Eli and Edythe Broad Stem Cell Research Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
- * Correspondence: mtouma@mednet.ucla.edu

Abstract: Advancements in genomics, bioinformatics, and genome editing have uncovered new dimensions in gene regulation. Post-transcriptional modifications by the alternative splicing of mRNA transcripts are critical regulatory mechanisms of mammalian gene expression. In the heart, there is an expanding interest in elucidating the role of alternative splicing in transcriptome regulation. Substantial efforts were directed toward investigating this process in heart development and failure. However, few studies shed light on alternative splicing products and their dysregulation in congenital heart defects (CHDs). While elegant reports showed the crucial roles of RNA binding proteins (RBPs) in orchestrating splicing transitions during heart development and failure, the impact of RBPs dysregulation or genetic variation on CHDs has not been fully addressed. Herein, we review the current understanding of alternative splicing and RBPs' roles in heart development and CHDs. We discuss the impact of perinatal splicing transition and its dysregulation in CHDs. We further summarize the discoveries made of causal splicing variants in key transcription factors that are implicated in CHDs. An improved understanding of the roles of alternative splicing in heart development and CHDs may potentially inform novel preventive and therapeutic advancements for newborn infants with CHDs.

Keywords: posttranscriptional modification; alternative splicing; congenital heart defects; transcriptome; splicing variants; genome



Citation: Mehta, Z.; Touma, M. Post-Transcriptional Modification by Alternative Splicing and Pathogenic Splicing Variants in Cardiovascular Development and Congenital Heart Defects. *Int. J. Mol. Sci.* **2023**, *24*, 1555. <https://doi.org/10.3390/ijms24021555>

Academic Editor: Chianshiu Chien

Received: 23 December 2022

Revised: 8 January 2023

Accepted: 9 January 2023

Published: 13 January 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The genome era has introduced new opportunities to understand - novel mechanisms of gene regulation, including post-transcriptional regulation by alternative splicing mechanisms. Orchestrated by the splicing machinery, RNA splicing is a highly regulated post-transcriptional modification process by which introns are removed from nascent pre-mRNAs, leading to the generation of mature mRNAs for translation and protein synthesis [Figure 1]. In contrast to canonical “constitutive” splicing [Figure 2A], alternative splicing exhibits temporal regulation during cellular differentiation, orchestrating tissue homeostasis and organ development by fine-tuning their cellular properties, physiological functions, and developmental trajectories. Meanwhile, dysregulated splicing networks may lead to impaired organ formation and function. Diverse physiological conditions and environmental stimuli may alter splicing decisions leading to the generation of multiple mRNA isoforms from a single gene in tissue-specific and context-dependent manners. This supports the concept that alternative splicing plays crucial roles in proper organ formation and function during the critical stages of mammalian development.




Figure 1. Schematic Representation of Alternative Splicing Process. Alternative splicing leads to functional diversity of transcriptome and proteome by creating a diverse array of protein isoforms from a single gene. Different colors represent different exons and corresponding changes in protein isoforms due to alternative splicing.




Figure 2. Schematic Representation of Most Common Alternative Splicing Pattern. (A) Constitutive splicing. (B–F) Alternative splicing modes. Skipped exon (B), alternative 5' splice site selection (C), alternative 3' splice site selection (D), retained intron (E), and mutually exclusive exon (F). Different colors represent different exons.

Transcripts from most protein-coding genes in mammals are subject to one or more types of alternative splicing [1,2]. Several alternative splicing types or patterns were described [Figure 2B–F]. Among them, five patterns are most encountered: (1) exon skipping (SE), (2) mutually exclusive exon (MEX) usage, (3) alternative 5' splice site selection (5'SS), (4) alternative 3' splice site selection (3'SS), and (5) intron retention (IR) [3].

Remarkably, ES is the most prevalent pattern, in which specific exons, referred to as cassette exons, are either included or skipped from the mature transcript depending on splicing decisions. MEX is less common than ES. In this pattern, one cassette exon is included, while the other is skipped in the mature transcript. The usage of alternative splice start sites or end sites affects the 5' or 3' ends, respectively, resulting in shorter or longer forms of exons from the same transcripts. Finally, IR occurs when intronic intervals are retained in the mature transcript, which may be translated or processed by a nonsense-mediated decay mechanism. Alternative splicing reactions are catalyzed by the spliceosome [4]. Spliceosome assembly involves the complex interplay of small nuclear ribonucleoprotein particles (snRNPs, U1, U2, U4/U6, and U5) and other associated proteins. The formation of spliceosomes and their mechanism of action were elegantly investigated and characterized using cryo-electron microscopy studies [5–8].

Alternative splicing is a ubiquitous process throughout organs, tissues, and cell types. In humans, transcripts of more than 95% of the protein-coding genes are estimated to undergo alternative splicing leading to proteome complexity [9]. In contrast to promoter activity regulation by transcription factors that predominantly affect transcript abundance, alternative splicing events affect mRNAs' structure and their translation potentials to functional protein isoforms that can exert diverse tissue specificity, cellular localization, binding ability, or enzymatic activity [10]. Furthermore, by altering the reading frame, alternative splicing may affect mRNA localization or translation, leading to protein isoforms of diverse and sometimes opposing functions [11]. The prevalence of alternative splicing has raised questions about its biological importance and functional outcomes. Therefore, establishing the partition of this process in human organ development and disease remains challenging. Indeed, not all splicing products lead to functionally intact protein isoforms at the translational level due to several reasons, amongst them: (1) the splicing event may produce a non-coding transcript lacking a functional open reading frame; (2) the splicing event may lead to a functional non-coding transcript that modulates chromatin accessibility or competes with other RNAs; (3) the splicing event may affect transcript stability leading to antisense mediated decay; (4) the splicing event may alter the subcellular localization of the mature mRNA impairing its translation or function; (5) the nonsense-mediated decay of premature stop codon-containing transcripts; and (6) the splicing events may be overestimated as a result of amplification artifacts.

Alternative splicing events are relatively poorly conserved; however, alternatively spliced exons that exhibit tissue specificity or distinct regulation patterns in response to changes in physiological status or external cues tend to be more conserved at the protein level suggesting putative functional outcomes [12]. Furthermore, large-scale analyses of AS atlases across seven different mammalian species during development suggest that dynamically regulated alternative splicing transitions during organ development tend to be more evolutionarily conserved than the nondynamic, more frequent splicing events [13]. Nevertheless, the extent of alternative splicing and the selection of splicing patterns tend to be different across organs, developmental periods, and types of cassette exons [13].

2. Regulation of Alternative Splicing

Operated by the splicing machinery, or the spliceosome, alternative splicing events are driven by various cis-regulatory elements located at the exon-intron boundaries. These splicing enhancer sequences orchestrate splicing decisions by recruiting RNA-binding proteins (RBPs) and other *trans*-acting factors that bind to the RNA molecule and define the exon-intron junctions [14]. Among the most investigated RBPs that contribute to the exon-intron definition are the serine/arginine (SR)-rich proteins (SF2/ASF, SRp20, SRp40, SRp55, and SRp75), the heterogeneous ribonucleoprotein (hnRNP) family of proteins (PTB, hnRNPA1, hnRNP C, hnRNP D, hnRNP E, hnRNP F/H, hnRNP G, and hnRNPH), and the RBPs containing RNA recognition motif (RRM), K homology domain (KH), and zinc-finger domains [15,16].

Upon binding the *cis*-elements at intron-exon junctions, RBPs promote or repress splice site interactions. Thus, they regulate the splice site selection at an early stage of the spliceosome formation [17,18], although they may contribute to the advanced stages of spliceosome assembly as well [4]. Initially, U1 ribonucleoprotein binds to the 5′ splice site (5′ss), while U2AF, a conserved heterodimer that plays a vital role in defining functional 3′ splice sites (3′ss) in pre-mRNA splicing, binds to the 3′ss and the poly-pyrimidine tract (YYY-rich). These early interactions lead to the recruitment of U2 snRNP to the pre-mRNA splice site, followed by the addition of tri-snRNP particles composed of U4/U6 and U5 snRNPs [Figure 3] [19]. Subsequently, RNA helicases facilitate rearrangements of snRNP interactions in the assembled spliceosome, which in turn catalyzes the splicing event [4]. Remarkably, the mutagenesis of minigene reporters demonstrated that splicing efficiency requires cooperative interactions of many RBPs that bind with “multivalent” motifs proximal to alternative exons to carry out the splicing reaction precisely [18,20].




Figure 3. Schematic Illustration of Spliceosome Assembly. Alternative splicing (AS) of a pre-mRNA is carried out by the spliceosome complex. U1 ribonucleoprotein binds to the 5′ splice site, while U2AF binds to the 3′ splice site and the poly-pyrimidine tract (YYY-rich). RNA-binding proteins (RBPs), such as SR proteins, bind to the splicing recognition motif. U2 ribonucleoprotein mediates the interaction between U1 ribonucleoprotein and U2AF, leading to a conformational change of the RNA-promoting binding of the tri-ribonucleoprotein complex (U4–U5–U6). Modified after Figure 1 in Biamonti et al. (Cells 2020, 9, 34; doi:10.3390/cells9010034) [19]. Copyright licence: <https://creativecommons.org/licenses/by/4.0/>.

In summary, alternative splicing regulation is carried out by multiple regulatory factors, acting in *cis* or *trans*, to achieve a precise definition of splicing sites. However, to date, the repertoires of proteins that control alternative splicing are not fully characterized. Employing long-read sequencing and examining RNP covalent interactions in post-transcriptional regulation, alongside the current advances in functional genomics and CRISPR-based approaches for modulating splicing, are expected to unfold the complexity of alternative splicing-mediated transcriptome regulation [20–26]. New sequencing technologies, such as single-cell RNA seq and Nanopore sequencing, are already implemented in neuroscience and cancer biology [27–29] and more recently in cardiovascular disease [30], revealing cell-type specific alternative splicing events and their functional impacts on cell behavior and fate. Considering that impaired splicing can lead to various human diseases [31–36], efforts tailored to the baseline understanding of tissue-specific and cell-specific alternative splicing processes and their physiologic roles are essential to reveal their contribution to human disease.

3. Alternative Splicing Transition during Heart Development

Heart development is a highly dynamic process during which significant transcriptome remodeling occurs in a spatial–temporal regulated manner [37,38]. These changes are driven mainly by transcriptional and post-transcriptional modification mechanisms, including alternative mRNA splicing.

Advanced genome-wide sequencing and functional genomics tools revealed significant splicing transitions during the differentiation of human embryonic stem cells into cardiac precursors [39,40]. They also uncovered significant differences in alternative splicing patterns between fetal and adult hearts [41,42]. Compared to the adult heart, RI events were found to be more predominant in the fetal heart. Furthermore, cellular proliferation processes were enriched in the fetal-specific alternative splicing events. In contrast, adult-specific events were enriched in energy-related categories [3]. Calcium channel beta2 (CACNB2), tropomyosin 1 (TPM1), disabled-1 (Dab1) [43,44], as well as important cell cycle regulators including, pumilio RNA-binding family member 1 (PUM1), calcium/calmodulin-dependent protein kinase 2D (CAMK2D), and anaphase-promoting complex subunit 11 (ANAPC11), exhibit significant splicing differences between fetal and adult hearts [3]. Likewise, sarcomere-related proteins are developmentally regulated via alternative splicing, including cardiac troponin T (cTnT). Exon 5 of cTnT is predominantly expressed in the embryonic heart, encoding a protein domain that increases embryonic cTnT-containing myofilament sensitivity to calcium, as compared to the less sensitive adult cTnT myofilaments, thereby modulating the contractile properties of embryonic myocardium [45,46]. More recently, single-cell RNA sequencing analysis of 996 samples representing the cellular composition of fetal-like (hiPSC-derived cardiac progenitors), healthy adult hearts, and diseased failing hearts further addressed the cellular heterogeneity of fetal and adult hearts [30]. The study also revealed significant reversion of fetal-specific RBPs in the diseased failing hearts that were associated with the re-induction of approximately 1500 fetal-specific isoforms compared to healthy adult hearts [30]. Remarkably, the reactivated fetal-specific isoforms tend to harbor RBP binding sites, have canonical splice site sequences, and contain known upstream polypyrimidine tracts.

Like in prenatal development, alternative splicing transition continues to play an important role as a regulatory component of transcriptomes in the early postnatal development of the murine heart. During this period, dramatic hemodynamic changes occur, driving significant alterations in cellular respiration, metabolism, proliferation, and functional properties. These changes are associated with a highly coordinated alternative splicing program that produces substantial protein isoform transitions that play critical roles in postnatal heart growth and maturation [47]. Using bulk RNA sequencing, transcriptome dynamics in mouse heart cells, cardiomyocytes, and cardiac fibroblasts, at different prenatal and postnatal stages were recently revealed [48]. While significant splicing changes in cardiomyocytes occur within the first month after birth, indicating an important role of alternative splicing in cardiomyocyte maturation, splicing transitions in cardiac fibroblasts continue beyond the first month. Finally, it is worth noting that alternative splicing products during postnatal heart development are more likely to exert functional consequences when the splicing transition occurs simultaneously in more than one organ, such as splicing events in the heart and brain during development [49–53].

Alternative splicing transitions during heart development are regulated by multiple of RBPs that exhibit significant temporal changes in their expression levels, exerting their functions in cooperative or antagonistic manners [54–56]. Out of approximately 1500 RBPs expressed in the heart, 390 cardiac-specific RBPs were identified [54]. Examples of cardiac RBPs that were principally investigated in heart development include *CELF1* (CUGBP Elav-like family member-1), *MBNL1* (muscleblind-like protein-1), *RBFOX1*, *RBFOX2*, *RBM20*, and *RBM24*, among several others [54–59]. Studies showed that the MBNL and CELF families play leading roles in the splicing transition during pre- and postnatal heart development [47,49,60]. Like their expression regulation during development, they often lead to reciprocal changes in their shared splicing targets, suggesting antagonistic regulation [49].

While MBNL1 was induced, CELF proteins were suppressed in the postnatal heart. Importantly, both *MBNL1* and *CELF* are regulated by RBM20-mediated alternative splicing during heart development. Correspondingly, *RBM20* loss of function in the adult heart reverts their levels to the embryonic splicing pattern. *Rbfox1* was also identified as a vital regulator for the conserved splicing process of transcription factor *Mef2* family members and was found to be a major player in the reversion of global fetal gene programming in pressure overload heart failure [58].

The identification of the downstream targets of several cardiac RBPs and splicing regulators [Table 1] provided important insights into how these factors can affect heart developmental decisions, physiology, and function [54–62]. During the mammalian heart development, RBPs orchestrate the alternative splicing of sarcomere genes that determine the structure and mechanical properties of the heart muscle, best exemplified by the splicing events in *Titin*, which contain the largest number of exons that may be alternatively utilized via splicing regulation, thereby modulating the Titin-based passive tension that determines diastolic ventricular filling. For example, exons 50–219 are shown to be developmentally regulated, with the longer protein isoform (N2BA) predominantly expressed in neonatal hearts, while the shorter protein isoform (N2B) is predominantly expressed in adult hearts [63]. Importantly, this shift toward higher N2B Titin isoform levels increases sarcomere-passive tension and myocardial stiffness. Hence, the relative abundance of the N2BA isoform compared to the N2B isoform determines the myocardium elasticity that controls ventricular filling during diastole [63]. Remarkably, in response to pressure overload, the left ventricles of patients with aortic stenosis exhibit a shift in Titin isoform expression toward the shorter N2B isoform. Consequently, the higher passive tension upon stretch may lead to a decline in cardiac performance [64]. Importantly, the Titin splicing at the PVEK region, which forms the I band with N2BA, is regulated by *RBM20* [63]. Hence, loss-of-function mutations in human *RBM20* have previously been shown to cause hereditary cardiomyopathy due to impaired Titin isoform transition and excessive production of the N2BA isoform in the *RBM20*-deficient hearts leading to weak Titin filaments and replacement fibrosis [63].

Table 1. RNA binding proteins and their main targets in heart development.

| RNA Binding Protein | Main Target(s) | CHD/Condition | References |
|---------------------|---|--------------------------------------|------------|
| RBFOX1 | <i>MEF2</i> | Heart Failure/Fetal-like program | [44] |
| RBM24 | <i>LDB4</i> , <i>CAMKIIδ</i> , <i>TPM</i> , <i>MyoM</i> | Sarcomerogenesis | [51,54–56] |
| RBM20 | <i>TTN</i> | Ventricular Elasticity | [52,53] |
| CELF1 | Fetal-like program | Heart Development/ Myofibrinogenesis | [57,64,65] |
| MBNL1 | Fetal-like Program | Heart Development | [57,64,65] |
| SRp38 | Triadin | Excitation-Contraction Coupling | [62] |
| ASF/SF2 | <i>CAMKIIδ</i> | Excitation-Contraction Coupling | [63] |
| RBpms | <i>Pdlim5</i> | Left Ventricle Noncompaction | [66] |
| RBFOX2 | <i>Rho GTPases</i> | Hypoplastic Left Ventricle | [67] |
| TBX5/SC35 | <i>RNF</i> | Holt-Oram Syndrome | [68] |

RBM24 is another RBP involved in cardiomyogenesis, and together with RBM20, regulates alternative splicing events of various sarcomere genes, including those encoding myomesin, tropomyosins, *LDB3*, and calcium/calmodulin-regulated kinase II delta (*CaMK II δ*) [62,65,69,70]. The changes in the isoform expression of these genes were implicated in dilated cardiomyopathy and impaired calcium handling in cardiomyocytes. Furthermore, the cholinergic receptor muscarinic 2 (*CHRM2*) was identified as a target for RBM24, revealing a new mechanism by which *RBM24* variants may modulate cardiac conduction and contractility [65,70]. SRp38 was also found to regulate cardiomyocyte contractility. The loss of *SRp38* in mice disturbed the splicing of triadin, a protein that controls calcium release from the sarcoplasmic reticulum during excitation–contraction (E–C) coupling [71]. Likewise, cardiomyocyte-specific ablation of SF2/ASF resulted in the impaired postnatal splicing switch of *CAMK II δ* , leading to a defect in the E–C coupling, dilated cardiomy-

opathy, and heart failure [72]. More recently, Quaking (QKI), an hnRNP protein [35], was identified as a critical alternative splicing regulator in cardiomyocyte differentiation and maturation that is required for heart development and function.

4. Dysregulated Alternative Splicing in Congenital Heart Defects (CHDs)

4.1. Splicing Transition in CHDs

Only recently has the role of alternative splicing in CHDs gained further attention. Global transcriptome profiling studies helped examine alternative splicing partitions in different CHD phenotypes. In the following, we highlight some representative studies and reference the other equally important literature [Table 2].

Table 2. Summary of Topics Highlighted in the Review. TOP cardiac-enriched genes encoding RNA binding proteins and other cardiac genes that are affected by alternative splicing or splicing variants are listed based on their functional categories.

| Alternative Splicing in Congenital Heart Disease |
|--|
| RNA Binding Protein Genes |
| <i>RBM10, RBM20, RBM24, RBFOX1, RBFOX2, SC35, SFB31, ASF/SF2, RBFOX2, RBpms, PUM1, CELF1, MBNL1, SRp38</i> |
| Splice Variants/Cardiac Transcription Regulators |
| <i>TBX5, GATA4, HAY2 RCAN1</i> |
| Splice Variants/Cardiac Conduction Genes |
| <i>PKP2, KV11.1</i> |
| Cardiac Structure/Sarcomere Genes |
| <i>FBN1, TTN, TNNT2, TPM1, MyoM, LDB3</i> |

Bicuspid aortic valve (BAV) is a common CHD affecting 0.5–2.0% of the general population and associated with risks for aortic dilatation and dissection. Using Affymetrix exon arrays, Fibronectin (FN) splicing isoforms were analyzed in dilated and nondilated ascending aorta from human BAV samples (n=69) and normal tricuspid aortic valve (TAV) samples (n = 40). An alternatively spliced extra domain A of FN (EDA-FN), which is essential for tissue repair, was found to be correlated with the maximum diameter of TAV but did not increase in dilated aorta tissues from BAV [73]. Remarkably, transforming growth factor- β (TGF β) treatment increased EDA-FN isoform expression in the cultured cells derived from TAV patients but not in the cells derived from BAV patients. Together, this indicates that differences in the TGF β signaling pathway may explain the impaired inclusion of EDA-FN in BAV patients.

Hypoplastic left heart syndrome (HLHS) is a serious and complex form of CHD, characterized by left ventricle hypoplasia and single ventricle physiology, with compensatory hypertrophy and hemodynamic overload of the right ventricle (RV). Using a genome-wide Affymetrix exon array, an extensive transcriptome analysis, including characterizing alternative splicing profiles, of the RV of six HLHS patients and the RV and left ventricle (LV) from control subjects, revealed distinct differential gene expressions and alternative splicing events in the RV myocardium of the HLHS patients compared to the RV and LV from the control heart, representing a unique molecular signature of HLHS, involving 180 differentially expressed genes and 1800 differentially spliced transcripts that were enriched in cell metabolism, cytoskeleton, and cell adhesion. Furthermore, some dysregulated genes can be quantified in plasma samples and serve as molecular biomarkers for prognostication classification. Such examples include those involved in calcium transporters (*SLC8A1* and *CACNB2*) and energy production (*COX4I1* and *ATP4A1*) as well as secreted factors (*IFI44* and *VEGFA*) [74].

Tetralogy of Fallot (TOF) is the most common cyanotic CHD phenotype that is typically associated with significant remodeling of the RV outflow tract (RVOT) due to pulmonary stenosis. By characterizing alternative splicing in RVOT specimens obtained from TOF patients, the small cajal body-specific RNA 1 (scaRNA1) was found to be downregulated-. Mechanistically, scaRNA1 loss in the primary cultured cells derived from the right ventricle

of TOF patients dysregulated the splicing of important regulators of heart development, including *GATA4*, *NOTCH2*, *DICER1*, *MBNL1*, and *MBNL2*. *themis*-splicing of the cardiac development genes was also observed in Zebrafish in response to the morpholino-mediated silencing of *scaRNA1* and was associated with decreased pseudouridylation in Spliceosomal RNA U2, potentially leading to reduced communication between the first and second heart fields and conotruncal misalignment, the hallmark in TOF [75].

Ventricular noncompaction is characterized by abnormal ventricular trabeculation and progressive cardiac dysfunction. The genetic cause of this disorder remains elusive. RNA-binding protein with multiple splicing (Rbpms) is highly expressed in the heart and contains a conserved RNA recognition motif (RRM) [76]. A recent report [66] demonstrated that genetic deletion of a novel Rbp with multiple splicing (Rbpms) leads to early lethality in neonatal mice caused by CHDs. Mechanistically, the Rbpms-depleted cardiomyocytes undergo an early exit from the cell cycle. This cytokinesis defect was also observed in human iPSCs-derived cardiomyocytes that carried the *RBPMS* gene deletion and were found to be associated with dysregulated RNA splicing of genes enriched in cytoskeletal signaling pathways, including the cardiac enriched LIM domain protein 5 (Pdlim5). Specifically, the Rbpms loss resulted in a substantial increase in Pdlim5-short isoforms that impaired cardiomyocyte division and resulted in premature binucleation, leading to ventricular noncompaction.

DiGeorge syndrome results from a micro-deletion located on the short arm of chromosome 22, which includes the *HIRA* gene and is commonly associated with TOF and other CHDs. It was shown that an intronic sequence (22k48) transcribed by the *HIRA* opposite strand, but not translated, undergoes alternative splicing [77]. Importantly, the haploinsufficiency of this intronic sequence may lead to the stigmata of DiGeorge syndrome, including CHDs, indicating that the non-coding intron retention mechanism of splicing can potentially exert pathogenic impacts on CHDs.

4.2. Role of Pathogenic Variants in RBPs in CHDs

Evidence from the human genetics and mouse models implicated pathogenic variants in RBPs in CHDs by impairing the splicing of their target genes [Table 2]. For example, the pathogenic variants in *RBM10*, a ubiquity expressed RBP, are known to cause TARP (Talipes equinovarus, Atrial septal defect, Robin sequence, and Persistent left superior vena cava) syndrome, an X-linked disorder that affects males [78–80]. Pathogenic variants in *RBFOX2* were implicated in HLHS [81]. Furthermore, *RBFOX2* may contribute to transcriptome dysregulation in RVs from HLHS patients [67]. Indeed, it was demonstrated that most of the transcripts that are differentially regulated in HLHS compared to control are targets for *RBFOX2* with 3'UTR binding sites contributing to mis-splicing [67]. Moreover, conditional deletion of *Rbfox2* in mouse embryos led to perturbation of yolk sac angiogenesis and complex heart defects recapitulating several features of HLHS. Remarkably, *Rbfox2* mutant heart-derived transcriptomes analysis identified dysregulated alternative splicing affecting extracellular matrix (ECM) and cellular adhesion networks. This was found to be mediated by Rho GTPases, two of which were identified as targets for *Rbfox2* [59]. By affecting the splicing of their downstream sarcomere gene products, such as Titin, pathogenic *RBM20* variants can cause human arrhythmogenic dilated cardiomyopathies (DCMs) and sudden cardiac death by disrupting the Ca^{2+} handling [63,68,82]. However, no disease-associated *RBM24* variants have been described to date.

Among the key core transcription factors in heart development is *TBX5*, a T-box transcription factor that is required for heart and limb morphogenesis. Pathogenic variants in *TBX5* are a known cause of Holt–Oram syndrome featured by CHDs and forelimb maldevelopment. Other than the known role of *TBX5* in transcription regulation, it was also demonstrated that *TBX5* plays a role in pre-mRNA splicing via the forming of a complex with the splicing factor SC35, an SR protein that was shown to be an essential splicing factor involved in spliceosome assembly and a regulator of alternative splicing [68]. Specifically, *TBX5* acted as an RBP with high specificity to the 5'ss of the *ANF* minigene but not to the 3'ss. Intriguingly, *TBX5* overexpression improved the splice site definition

and enhanced the splicing efficiency of *ANF* mediated by SC35. Moreover, the pathogenic variant (G80R) that affects TBX5 splicing performance is directly linked to the pathogenesis of Holt–Oram syndrome and featured with complete penetrance of CHDs due to significant mis-splicing of mRNA. In contrast, other variants that do not affect TBX5 splicing function usually have incomplete penetrance in CHDs [83].

4.3. Role of Splicing Site Variants in CHDs

Advances in genomics platforms improved the detection of rare pathogenic splicing genomic variants that alter canonical splice sites, thus resulting in splicing and functional defects of their genes or impacting their promoter activity and regulatory elements. Nonetheless, establishing the causal roles of these variants and identifying their downstream targets in CHDs remain challenging. Few reports described pathogenic splicing variants in key cardiac transcription regulators or structural genes leading to developmental perturbation and CHDs [Table 3]. *GATA4*, which encodes GATA Binding Protein 4, is a key transcription factor that plays an important role in cardiac development and was implicated in CHDs. By performing analysis of the *GATA4* variant in an Indian patients with CHDs, two intronic splice site variants ([g.83271C>A/M] and [g.86268A>R]) were predicted to affect intronic splice sites at the enhancer and silencer motifs based on in silico prediction analysis, indicating that the non-coding pathogenic splicing variant can introduce splicing defects that lead to CHDs [84].

Table 3. Genes affected by pathogenic splicing variants and their contribution to CHDs. Notes: TARP: Talipes equinovarus, Atrial septal defect, Robin sequence, and Persistent left superior vena cava; ARVD: Arrhythmogenic Right Ventricle Dysplasia; AVSD: Atrial Ventricular Septal Defect.

| Reference Citation | Affected Gene | Variant | Phenotypes |
|--|------------------|--|---------------------------|
| [63] Guo et al. <i>Nat Med</i> (2012) 18 (5), 766–773 | <i>RBM20</i> | S635A | Dilated Cardiomyopathy |
| [78] Wang Y et al. <i>EMBO Mol Med</i> (2013) 5,1431–1442 | <i>RBM10</i> | Del of 1292nucleotides (ChrX: 46929367–46930658 bp) | TARP Syndrome/CHD |
| [79] Tessier et al. <i>BMB Research Notes</i> (2015) 8,46 | <i>RBM10</i> | Tandem donor splice site (GTGGTG) in <i>RBM10</i> exon 10 | TARP Syndrome/CHD |
| [80] Johnston JJ et al. <i>The American Journal of Human Genetics</i> (2010) 86,743–748 | <i>RBM10</i> | c.1235G>A; c.1893_1894insA | TARP Syndrome/CHD |
| [82] Beqqali A et al. <i>Cardiovascular Research</i> (2016) 112, 452–463 | <i>RBM20</i> | c.2737G>A | Dilated Cardiomyopathy |
| [68] van den Hoogenhof et al. <i>Circulation</i> (2018) 138, 1330–1342. | <i>RBM20</i> | Multiple Variants | Dilated Cardiomyopathy |
| [83] Fan C et al. <i>The Journal of Biological Chemistry</i> (2009) 284, 38, 25653–25663 | <i>TBX5/SC35</i> | G80R | HOLT–Oram Syndrome/CHD |
| [84] Bose D. et al. <i>Mutat Res Fund</i> (2017) 803–805, 26–34 | <i>GATA4</i> | g.83271C>A/M (intronic variant); g.86268A>R (intronic Variant) | Nonsyndromic ASD/VSD/AVSD |
| [85] Li X et al. <i>Pediatr Cardiol</i> (2018) 39, 226–235 | <i>RCAN1</i> | g.482G>T (intronic variant) | Nonsyndromic ASD/VSD/AVSD |
| [86] Fusco C et al. <i>Genes</i> (2019) 10 (6), 442 | <i>FBN1</i> | c.6872–24T>A; c. 7571–12T>A | Marfan’s Syndrome/CHD |
| [87] Gong Q et al. <i>Circ Cardiovascular Gent</i> (2014) 7 (4), 482–490 | <i>KCNH2</i> | IVS9–2delA (a deletion of the A in AG dinucleotide of the 3’ acceptor site of <i>KCNH2</i> intron 9) | Long QT Syndrome |
| [88] Awad MM et al. <i>Human Mutat</i> (2006) 27 (11), 1157. | <i>PKP2</i> | c. 2484C>T + c.2484C>T | ARVD |

Othersplicing variants of key regulatory genes may contribute to CHDs. One example is the Regulator of Calcineurin 1 (*RCAN1*), which was linked to CHDs associated with Down syndrome. To examine if *RCAN1* contributes to non-syndromic cases of CHDs, *RCAN1* exons and flanking regions from 128 patients with non-syndromic CHD and 150 normal controls were sequenced, leading to the detection of six novel heterozygous variants in the *RCAN1* gene in CHD cases, although they were absent in control cases. In particular, the g.482G>T

variant was found to enhance *RCAN1* promoter activity leading to overexpression of the *RCAN1.4* isoform, potentially causing CHDs in the absence of Down syndrome [85].

Pathogenic splicing variants in genes encoding structural proteins were also implicated in CHDs. Encoded by *FBN1*, Fibrillin 1 is a key constituent of ECM. Pathogenic *FBN1* variants are linked to Marfan's syndrome (MFS) and mitral valve–aorta–skeleton–skin (MASS) syndrome. However, *FBN1* variants are mostly enriched in intronic sequences, making the prediction of their pathogenicity and establishing the genotype-phenotype correlations very challenging. A recent study [86] reported two *FBN1* deep intronic variants ([c.6872-24T>A] and [c.7571-12T>A]) in two unrelated patients who were affected with MFS/aortic disease and MASS syndrome, respectively. Remarkably, both variants led to the retention of intronic regions, resulting in changes in the reading frame and the introduction of premature stop codons. The pathogenic variants of RBPs and the splice site variants in CHDs are summarized in [Table 3].

4.4. Splicing Variants Leading to Congenital Conduction Defects (Arrhythmias)

Pathogenic splicing variants may affect ion channel assembly and function, leading to developmental defects in conduction. It has been shown that the potassium channel (Kv11.1) isoform switch represents a novel mechanism of the congenital long-QT syndrome. A novel splice site variant in *KCNH2*, which encodes Kv11.1, was detected in an expanded family, affecting the relative abundance of the full-length Kv11.1a isoform and the truncated Kv11.1a-USO isoform. This, in turn, was dictated by the competition between *KCNH2* alternative splicing and the alternative polyadenylation mechanisms [87]. Splicing defects may also impair voltage-gated sodium channels. A recent report demonstrated that a non-muscle isoform of *RBFOX2* [*RBFOX2*₄₀] is upregulated in heart tissue from myotonic dystrophy 1 (DM1) patients leading to elevated *CELF1* and a global miRNA suppression [23]. By modeling in mice, *Rbfox2*₄₀ isoform overexpression caused a mis-splicing of the voltage-gated sodium channel transcripts, creating a pro-arrhythmic status that altered the channel electrical properties leading to conduction defects.

Arrhythmogenic right ventricle dysplasia (ARVD) is a rare inherited disorder that involves the replacement of RV cardiomyocytes with fibro adipose tissues that consequently leads to ventricular arrhythmias. ARVD cases with dominant inheritance and incomplete penetrance are caused by heterozygous *PKP2* mutations. Interestingly, the first reported ARVD case with recessive inheritance was caused by a homozygous cryptic splice variant in *PKP2* (c.2484C>T), which was initially annotated as a synonymous variant [88]. However, further analysis of the proband's mRNA uncovered the disruption of the *PKP2* reading frame and alteration of *PKP2* splicing outcomes caused by this cryptic splice site variant leading.

5. Conclusions

Alternative splicing is a ubiquitous process that plays important roles in transcriptome regulation and proteome diversity. The current literature evidence supports the important regulatory roles of alternative splicing in cardiovascular development and CHDs. Splicing transition is controlled by a complex and intricate network of RBPs, which orchestrate the splicing transition of their targets during heart development and can be dysregulated in CHDs. Pathogenic variants of RBPs may alter the splicing decisions of their targets and account for substantial developmental perturbation leading to CHDs. Pathogenic splicing variants of key core cardiac transcription factors and structural genes can be causal to CHDs.

Taking into consideration the existing challenges in establishing the partition of his vital process in human heart development and disease, massive efforts tailored to a comprehensive baseline understanding of tissue-specific and cell-specific alternative splicing transitions and their physiologic roles during heart development are essential. Utilizing cutting-edge sequencing technology, such as single-cell and long-read RNA sequencing; examining RNP covalent interactions in post-transcriptional gene regulation, and employing functional genomics and CRISPR-based approaches for modulating splicing are expected to unfold the complexity of alternative splicing-mediated transcriptome regulation mecha-

nisms at the cell-type specific level and reveal their functional impacts on cell behavior and fate during development and their contributions to human CHDs. Multilayered collaborative bioinformatics, functional genomics, and mechanistic approaches for examining RBPs dysregulation and elucidating the causal impact of newly discovered splicing variants in CHDs are critical to uncover new mechanisms and pave the way to novel diagnostic and targeted approaches for infants with CHDs.

Author Contributions: Z.M. collected references and participated in manuscript writing and editing. M.T. conceived and designed the manuscript, generated figures, and completed manuscript writing and editing. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the 2021 UCLA Broad Stem Cell Research Center (BSCRC) T32 Training grant (Z.M.) and grants from NIH/NHLBI 1R01 HL153853-01 (M.T.), the Department of Defense-Congressionally Directed Medical Research Programs W81XWH-18-1-0164 (M.T.), and the 2022 UCLA Academic Senate Faculty Research Fund (M.T.).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: No Competing Interests. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Abbreviations

| | |
|-------|--|
| ARVD | Arrhythmogenic Right Ventricular Dysplasia |
| BAV | Bicuspid Aortic Valve |
| CHDs | Congenital Heart Defects |
| E-C | Excitation–Contraction |
| HLHS | Hypoplastic Left Heart Syndrome |
| LVNC | Left Ventricular Noncompaction |
| RBPs | RNA-Binding Proteins |
| RBPMS | RNA-Binding Protein with Multiple Splicing |
| RVOT | Right Ventricular Outflow Tract |
| TAV | Tricuspid Aortic Valve |
| TOF | Tetralogy of Fallot |

References

1. Ule, J.; Blencowe, B.J. Alternative Splicing Regulatory Networks: Functions, Mechanisms, and Evolution. *Mol. Cell.* **2019**, *76*, 329–345. [[CrossRef](#)]
2. Black, D.L. Mechanisms of alternative pre-messenger RNA splicing. *Annu. Rev. Biochem.* **2003**, *72*, 291–336. [[CrossRef](#)]
3. Wang, H.; Chen, Y.; Li, X.; Chen, G.; Zhong, L.; Chen, G.; Liao, Y.; Liao, W.; Bin, J. Genome-wide analysis of alternative splicing during human heart development. *Sci. Rep.* **2016**, *6*, 35520. [[CrossRef](#)] [[PubMed](#)]
4. Wahl, M.C.; Will, C.L.; Lührmann, R. The spliceosome: Design principles of a dynamic RNP machine. *Cell.* **2009**, *136*, 701–718. [[CrossRef](#)]
5. Kastner, B.; Will, C.L.; Stark, H.; Lührmann, R. Structural Insights into Nuclear pre-mRNA Splicing in Higher Eukaryotes. *Cold Spring Harb. Perspect. Biol.* **2019**, *11*, a032417. [[CrossRef](#)]
6. Plaschka, C.; Lin, P.C.; Nagai, K. Structure of a pre-catalytic spliceosome. *Nature* **2017**, *546*, 617–621. [[CrossRef](#)] [[PubMed](#)]
7. Yan, C.; Wan, R.; Shi, Y. Molecular Mechanisms of pre-mRNA Splicing through Structural Biology of the Spliceosome. *Cold Spring Harb. Perspect. Biol.* **2019**, *11*, a032409. [[CrossRef](#)]
8. Zhang, X.; Zhan, X.; Yan, C.; Zhang, W.; Liu, D.; Lei, J.; Shi, Y. Structures of the human spliceosomes before and after release of the ligated exon. *Cell Res.* **2019**, *29*, 274–285. [[CrossRef](#)]
9. Pan, Q.; Shai, O.; Lee, L.J.; Frey, B.J.; Blencowe, B.J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. *Nat. Genet.* **2008**, *40*, 1413–1415. [[CrossRef](#)]
10. Manning, K.S.; Cooper, T.A. The roles of RNA processing in translating genotype to phenotype. *Nat. Rev. Mol. Cell Biol.* **2017**, *18*, 102–114. [[CrossRef](#)] [[PubMed](#)]

11. Asselta, R.; Rimoldi, V.; Guella, I.; Soldà, G.; De Cristofaro, R.; Peyvandi, F.; Duga, S. Molecular characterization of in-frame and out-of-frame alternative splicings in coagulation factor XI pre-mRNA. *Blood* **2010**, *115*, 2065–2072. [[CrossRef](#)] [[PubMed](#)]
12. Wang, Y.; Liu, J.; Huang, B.; Xu, Y.; Li, J.; Huang, L.; Lin, J.; Zhang, J.; Min, Q.-H.; Yang, W.-M.; et al. Mechanism of alternative splicing and its regulation. *Biomed. Rep.* **2015**, *3*, 152–158. [[CrossRef](#)] [[PubMed](#)]
13. Mazin, P.V.; Khaitovich, P.; Cardoso-Moreira, M.; Kaessmann, H. Alternative splicing during mammalian organ development. *Nat. Genet.* **2021**, *53*, 925–934. [[CrossRef](#)]
14. House, A.E.; Lynch, K.W. Regulation of alternative splicing: More than just the ABCs. *J. Biol. Chem.* **2008**, *283*, 1217–1221. [[CrossRef](#)] [[PubMed](#)]
15. Lunde, B.M.; Moore, C.; Varani, G. RNA-binding proteins: Modular design for efficient function. *Nat. Rev. Mol. Cell Biol.* **2007**, *8*, 479–490. [[CrossRef](#)]
16. Eldridge, A.G.; Li, Y.; Sharp, P.A.; Blencowe, B.J. The SRm160/300 splicing coactivator is required for exon-enhancer function. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 6125–6130. [[CrossRef](#)] [[PubMed](#)]
17. De Conti, L.; Baralle, M.; Buratti, E. Exon and intron definition in pre-mRNA splicing. *Wiley Interdiscip. Rev. RNA* **2013**, *4*, 49–60. [[CrossRef](#)]
18. Fu, X.D.; Ares, M. Context-dependent control of alternative splicing by RNA-binding proteins. *Nat. Rev. Genet.* **2014**, *15*, 689–701. [[CrossRef](#)]
19. Biamonti, G.; Infantino, L.; Gaglio, D.; Amato, A. An Intricate Connection between Alternative Splicing and Phenotypic Plasticity in Development and Cancer. *Cells* **2019**, *9*, 34. [[CrossRef](#)]
20. Cereda, M.; Pozzoli, U.; Rot, G.; Juvan, P.; Schweitzer, A.; Clark, T.; Ule, J. RNAmotifs: Prediction of multivalent RNA motifs that control alternative splicing. *Genome Biol.* **2014**, *15*, R20. [[CrossRef](#)]
21. Gonatopoulos-Pournatzis, T.; Wu, M.; Braunschweig, U.; Roth, J.; Han, H.; Andrew, J.; Best, A.J.; Raj, B.; Aregger, M.; O’Hanlon, D.; et al. Genome-wide CRISPR-Cas9 Interrogation of Splicing Networks Reveals a Mechanism for Recognition of Autism-Misregulated Neuronal Microexons. *Mol. Cell.* **2018**, *72*, 510–524.e12. [[CrossRef](#)]
22. Konermann, S.; Lotfy, P.; Brideau, N.J.; Oki, J.; Shokhirev, M.N.; Hsu, P.D. Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors. *Cell* **2018**, *173*, 665–676.e14. [[CrossRef](#)] [[PubMed](#)]
23. Misra, C.; Bangru, S.; Lin, F.; Lam, K.; Koenig, S.N.; Lubbers, E.R.; Hedhli, J.; Murphy, N.P.; Parker, D.J.; Dobrucki, L.W.; et al. Aberrant expression of a non-muscle RBFOX2 isoform triggers cardiac conduction defects in myotonic dystrophy. *Dev. Cell.* **2020**, *52*, 748–763.e6. [[CrossRef](#)]
24. Anvar, S.Y.; Allard, G.; Tseng, E.; Sheynkman, G.M.; de Klerk, E.; Vermaat, M.; Yin, R.H.; Johansson, H.E.; Ariyurek, Y.; Dunnen, J.T.D.; et al. Full-length mRNA sequencing uncovers a widespread coupling between transcription initiation and mRNA processing. *Genome Biol.* **2018**, *19*, 46. [[CrossRef](#)]
25. Ding, F.; Elowitz, M.B. Constitutive splicing and economies of scale in gene expression. *Nat. Struct. Mol. Biol.* **2019**, *26*, 424–432. [[CrossRef](#)]
26. Fiszbein, A.; Krick, K.S.; Begg, B.E.; Burge, C.B. Exon-Mediated Activation of Transcription Starts. *Cell* **2019**, *179*, 1551–1565.e17. [[CrossRef](#)]
27. Manipur, I.; Granata, I.; Guarracino, M.R. Exploiting single-cell RNA sequencing data to link alternative splicing and cancer heterogeneity: A computational approach. *Int. J. Biochem. Cell Biol.* **2019**, *108*, 51–60. [[CrossRef](#)] [[PubMed](#)]
28. Lukacsovich, D.; Winterer, J.; Que, L.; Luo, W.; Lukacsovich, T.; Foldy, C. Single-Cell RNA-Seq Reveals Developmental Origins and Ontogenetic Stability of Neurexin Alternative Splicing Profiles. *Cell Rep.* **2019**, *27*, 3752–3759.e4. [[CrossRef](#)]
29. Boti, M.A.; Adamopoulos, P.G.; Tsiakanikas, P.; Scorilas, A. Nanopore Sequencing Unveils Diverse Transcript Variants of the Epithelial Cell-Specific Transcription Factor Elf-3 in Human Malignancies. *Genes* **2021**, *12*, 839. [[CrossRef](#)]
30. D’Antonio, M.; Nguyen, J.P.; Arthur, T.D.; Matsui, H.; Donovan, M.K.R.; D’Antonio-Chronowska, A.; Frazer, K.A. In heart failure reactivation of RNA-binding proteins is associated with the expression of 1,523 fetal-specific isoforms. *PLoS Comput. Biol.* **2022**, *18*, e1009918. [[CrossRef](#)] [[PubMed](#)]
31. Bonnal, S.; López-Oreja Valcárcel, J. Roles and mechanisms of alternative splicing in cancer—Implications for care. *Nat. Rev. Clin. Oncol.* **2020**, *17*, 457–474. [[CrossRef](#)]
32. Titus, M.B.; Wright, E.G.; Bono, J.M.; Poliakon, A.K.; Goldstein, B.R.; Super, M.K.; Young, L.A.; Manaj, M.; Litchford, M.; Reist, N.E.; et al. The conserved alternative splicing factor caper regulates neuromuscular phenotypes during development and aging. *Dev. Biol.* **2021**, *473*, 15–32. [[CrossRef](#)] [[PubMed](#)]
33. Watanabe, T.; Kimura, A.; Kuroyanagi, H. Alternative Splicing Regulator RBM20 and Cardiomyopathy. *Front. Mol. Biosci.* **2018**, *5*, 105. [[CrossRef](#)]
34. Joly, A.L.; Andersson, J. Alternative splicing, FOXP3 and cardiovascular disease. *Aging* **2019**, *11*, 1905–1906. [[CrossRef](#)]
35. Chen, X.; Liu, Y.; Xu, C.; Ba, L.; Liu, Z.; Li, X.; Huang, J.; Simpson, E.; Gao, H.; Cao, D.; et al. QKI is a critical pre-mRNA alternative splicing regulator of cardiac myofibrillogenesis and contractile function. *Nat. Commun.* **2021**, *12*, 89. [[CrossRef](#)]
36. Hasimbegovic, E.; Schweiger, V.; Kastner, N.; Spannbaauer, A.; Traxler, D.; Lukovic, D.; Gyöngyösi, M.; Mester-Tonczar, J. Alternative Splicing in Cardiovascular Disease—A Survey of Recent Findings. *Genes* **2021**, *12*, 1457. [[CrossRef](#)] [[PubMed](#)]
37. Meng, Z.; Wang, J.; Peng, J.; Zhou, Y.; Zhou, S.; Song, W.; Chen, S.; Wang, Q.; Bai, K.; Sun, K. Dynamic transcriptome profiling toward understanding the development of the human embryonic heart during different Carnegie stages. *FEBS Lett.* **2020**, *594*, 4307–4319. [[CrossRef](#)] [[PubMed](#)]

38. Touma, M.; Kang, X.; Gao, F.; Zhao, Y.; Cass, A.; Biniwale, R.; Xiao, X.; Coppola, G.; Reemtsen, B.; Wang, Y. Wnt11 Regulates Neonatal Cardiac Chamber Development During Perinatal Maturation. *JCI Insight* **2017**, *2*, e94904. [[CrossRef](#)] [[PubMed](#)]
39. Zhang, T.; Lin, Y.; Liu, J.; Zhang, Z.G.; Fu, W.; Guo, L.Y.; Pan, L.; Kong, X.; Zhang, M.K.; Lu, Y.H.; et al. Rbm24 Regulates Alternative Splicing Switch in Embryonic Stem Cell Cardiac Lineage Differentiation. *Stem Cells* **2016**, *34*, 1776–1789. [[CrossRef](#)]
40. Gabut, M.; Samavarchi-Tehrani, P.; Wang, X.; Slobodeniuc, V.; O'Hanlon, D.; Sung, H.K.; Alvarez, M.; Talukder, S.; Pan, Q.; Mazzoni, E.O.; et al. An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. *Cell* **2011**, *147*, 132–146. [[CrossRef](#)]
41. van den Hoogenhof, M.M.; Pinto, Y.M.; Creemers, E.E. RNA Splicing: Regulation and Dysregulation in the Heart. *Circ. Res.* **2016**, *118*, 454–468. [[CrossRef](#)] [[PubMed](#)]
42. Chothani, S.; Schäfer, S.; Adami, E.; Viswanathan, S.; Widjaja, A.A.; Langley, S.R.; Tan, J.; Wang, M.; Quaiife, N.M.; Pua, C.J.; et al. Widespread Translational Control of Fibrosis in the Human Heart by RNA-Binding Proteins. *Circulation* **2019**, *140*, 937–951. [[CrossRef](#)] [[PubMed](#)]
43. Takahashi, S.X.; Mittman, S.; Colecraft, H.M. Distinctive modulatory effects of five human auxiliary beta2 subunit splice variants on L-type calcium channel gating. *Biophys. J.* **2003**, *84*, 3007–3021. [[CrossRef](#)] [[PubMed](#)]
44. Gooding, C.; Smith, C.W. Tropomyosin exons as models for alternative splicing. *Adv. Exp. Med. Biol.* **2008**, *644*, 27–42. [[CrossRef](#)]
45. Cooper, T.A.; Ordahl, C.P. A single cardiac troponin T gene generates embryonic and adult isoforms via developmentally regulated alternate splicing. *J. Biol. Chem.* **1985**, *260*, 11140–11148. [[CrossRef](#)]
46. McAuliffe, J.J.; Gao, L.Z.; Solaro, R.J. Changes in myofibrillar activation and troponin C Ca²⁺ binding associated with troponin T isoform switching in developing rabbit heart. *Circ. Res.* **1990**, *66*, 1204–1216. [[CrossRef](#)] [[PubMed](#)]
47. Giudice, J.; Xia, Z.; Wang, E.T.; Scavuzzo, M.A.; Ward, A.J.; Kalsotra, A.; Wang, W.; Wehrens, X.H.; Burge, C.B.; Li, W.; et al. Alternative splicing regulates vesicular trafficking genes in cardiomyocytes during postnatal heart development. *Nat. Commun.* **2014**, *5*, 3603. [[CrossRef](#)]
48. Martí-Gómez, C.; Larrasa-Alonso, J.; López-Olañeta, M.; Villalba-Orero, M.; García-Pavía, P.; Sánchez-Cabo, F.; Lara-Pezzi, E. Functional Impact and Regulation of Alternative Splicing in Mouse Heart Development and Disease. *J. Cardiovasc. Transl. Res.* **2022**, *15*, 1239–1255. [[CrossRef](#)]
49. Kalsotra, A.; Xiao, X.; Ward, A.J.; Castle, J.C.; Johnson, J.M.; Burge, C.B.; Cooper, T.A. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 20333–20338. [[CrossRef](#)]
50. Barbosa-Morais, N.L.; Irimia, M.; Pan, Q.; Xiong, H.Y.; Gueroussov, S.; Lee, L.J.; Slobodeniuc, V.; Kutter, C.; Watt, S.; Colak, R.; et al. The evolutionary landscape of alternative splicing in vertebrate species. *Science* **2012**, *338*, 1587–1593. [[CrossRef](#)]
51. Ellis, J.D.; Barrios-Rodiles, M.; Colak, R.; Irimia, M.; Kim, T.; Calarco, J.A.; Wang, X.; Pan, Q.; O'Hanlon, D.; Kim, P.M.; et al. Tissue-specific alternative splicing remodels protein-protein interaction networks. *Mol. Cell.* **2012**, *46*, 884–892. [[CrossRef](#)] [[PubMed](#)]
52. Dillman, A.A.; Hauser, D.N.; Gibbs, J.R.; Nalls, M.A.; McCoy, M.K.; Rudenko, I.N.; Galter, D.; Cookson, M.R. mRNA expression, splicing and editing in the embryonic and adult mouse cerebral cortex. *Nat. Neurosci.* **2013**, *16*, 499–506. [[CrossRef](#)]
53. Trabzuni, D.; Ramasamy, A.; Imran, S.; Walker, R.; Smith, C.; Weale, M.E.; Hardy, J.; Ryten, M.; North American Brain Expression Consortium. Widespread sex differences in gene expression and splicing in the adult human brain. *Nat. Commun.* **2013**, *4*, 2771. [[CrossRef](#)]
54. Blech-Hermoni, Y.; Ladd, A.N. RNA binding proteins in the regulation of heart development. *Int. J. Biochem. Cell Biol.* **2013**, *45*, 2467–2478. [[CrossRef](#)] [[PubMed](#)]
55. Giudice, J.; Cooper, T.A. RNA-binding proteins in heart development. *Adv. Exp. Med. Biol.* **2014**, *825*, 389–429. [[CrossRef](#)]
56. Ladd, A.N. New Insights Into the Role of RNA-Binding Proteins in the Regulation of Heart Development. *Int. Rev. Cell Mol. Biol.* **2016**, *324*, 125–185. [[CrossRef](#)] [[PubMed](#)]
57. Blech-Hermoni, Y.; Sullivan, C.B.; Jenkins, M.W.; Wessely, O.; Ladd, A.N. CUG-BP, Elav-like family member 1 (CELF1) is required for normal myofibrillogenesis, morphogenesis, and contractile function in the embryonic heart. *Dev. Dyn.* **2016**, *245*, 854–873. [[CrossRef](#)] [[PubMed](#)]
58. Gao, C.; Ren, S.; Lee, J.H.; Qiu, J.; Chapski, D.J.; Rau, C.D.; Zhou, Y.; Abdellatif, M.; Nakano, A.; Vondriska, T.M.; et al. RBFOX1-mediated RNA splicing regulates cardiac hypertrophy and heart failure. *J. Clin. Investig.* **2016**, *126*, 195–206. [[CrossRef](#)]
59. Verma, S.K.; Deshmukh, V.; Thatcher, K.; Belanger, K.K.; Rhyner, A.M.; Meng, S.; Holcomb, R.J.; Bressan, M.; Martin, J.F.; Cooke, J.P.; et al. RBFOX2 is required for establishing RNA regulatory networks essential for heart development. *Nucleic Acids Res.* **2022**, *50*, 2270–2286. [[CrossRef](#)]
60. Wang, E.T.; Cody, N.A.L.; Joy, S.; Biancolella, M.; Wang, T.T.; Treasy, D.J.; Luo, S.; Schroth, G.P.; Housman, D.E.; Reddy, S.; et al. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. *Cell* **2012**, *150*, 710–724. [[CrossRef](#)]
61. Yang, J.; Hung, L.H.; Licht, T.; Kostin, S.; Looso, M.; Khrameeva, E.; Bindereif, A.; Schneider, S.; Braun, T. RBM24 is a major regulator of muscle-specific alternative splicing. *Dev. Cell.* **2014**, *31*, 87–99. [[CrossRef](#)] [[PubMed](#)]
62. Weeland, C.J.; van den Hoogenhof, M.M.; Beqqali, A.; Creemers, E.E. Insights into alternative splicing of sarcomeric genes in the heart. *J. Mol. Cell Cardiol.* **2015**, *81*, 107–113. [[CrossRef](#)]

63. Guo, W.; Schafer, S.; Greaser, M.L.; Radke, M.H.; Liss, M.; Govindarajan, T.; Maatz, H.; Schulz, H.; Li, S.; Parrish, A.M.; et al. RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. *Nat. Med.* **2012**, *18*, 766–773. [[CrossRef](#)] [[PubMed](#)]
64. Williams, L.; Howell, N.; Pagano, D.; Andreka, P.; Vertesaljai, M.; Pecor, T.; Frenneaux, M.; Granzier, H. Titin isoform expression in aortic stenosis. *Clin. Sci.* **2009**, *117*, 237–242. [[CrossRef](#)]
65. Poon, K.L.; Tan, K.T.; Wei, Y.Y.; Ng, C.P.; Colman, A.; Korzh, V.; Xu, X.Q. RNA-binding protein RBM24 is required for sarcomere assembly and heart contractility. *Cardiovasc. Res.* **2012**, *94*, 418–427. [[CrossRef](#)] [[PubMed](#)]
66. Gan, P.; Wang, Z.; Morales, M.G.; Zhang, Y.; Bassel-Duby, R.; Liu, N.; Olson, E.N. RBPMS is an RNA-binding protein that mediates cardiomyocyte binucleation and cardiovascular development. *Dev. Cell.* **2022**, *57*, 959–973.e7. [[CrossRef](#)]
67. Verma, S.K.; Deshmukh, V.; Nutter, C.A.; Jaworski, E.; Jin, W.; Wadhwa, L.; Abata, J.; Ricci, M.; Lincoln, J.; Martin, J.F.; et al. Rbfox2 function in RNA metabolism is impaired in hypoplastic left heart syndrome patient hearts. *Sci. Rep.* **2016**, *6*, 30896. [[CrossRef](#)]
68. van den Hoogenhof, M.M.G.; Beqqali, A.; Amin, A.S.; van der Made, I.; Aufiero, S.; Khan, M.A.F.; Schumacher, C.A.; Jansweijer, J.A.; van Spaendonck-Zwarts, K.Y.; Remme, C.A.; et al. RBM20 Mutations Induce an Arrhythmogenic Dilated Cardiomyopathy Related to Disturbed Calcium Handling. *Circulation* **2018**, *138*, 1330–1342. [[CrossRef](#)]
69. Gu, Q.; Jin, N.; Sheng, H.; Yin, X.; Zhu, J. Cyclic AMP-dependent protein kinase A regulates the alternative splicing of CaMKII δ . *PLoS ONE* **2011**, *6*, e25745. [[CrossRef](#)]
70. Lin, Y.; Tan, K.T.; Liu, J.; Kong, X.; Huang, Z.; Xu, X.Q. Global profiling of Rbm24 bound RNAs uncovers a multi-tasking RNA binding protein. *Int. J. Biochem. Cell Biol.* **2018**, *94*, 10–21. [[CrossRef](#)]
71. Feng, Y.; Valley, M.T.; Lazar, J.; Yang, A.L.; Bronson, R.T.; Firestein, S.; Coetzee, W.A.; Manley, J.L. SRp38 regulates alternative splicing and is required for Ca (2+) handling in the embryonic heart. *Dev. Cell.* **2009**, *16*, 528–538. [[CrossRef](#)] [[PubMed](#)]
72. Xu, X.; Yang, D.; Ding, J.H.; Wang, W.; Chu, P.-H.; Dalton, N.D.; Wang, H.-Y.; Birmingham, J.R.; Ye, Z.; Liu, F.; et al. ASF/SF2-regulated CaMKII δ alternative splicing temporally reprograms excitation-contraction coupling in cardiac muscle. *Cell* **2005**, *120*, 59–72. [[CrossRef](#)]
73. Paloschi, V.; Kurtovic, S.; Folkersen, L.; Gomez, D.; Wågsäter, D.; Roy, J.; Petrini, J.; Eriksson, M.J.; Caidahl, K.; Hamsten, A.; et al. Impaired splicing of fibronectin is associated with thoracic aortic aneurysm formation in patients with bicuspid aortic valve. *Arterioscler. Thromb. Vasc. Biol.* **2011**, *31*, 691–697. [[CrossRef](#)]
74. Ricci, M.; Xu, Y.; Hammond, H.L.; Willoughby, D.A.; Nathanson, L.; Rodriguez, M.M.; Vatta, M.; Lipshultz, S.E.; Lincoln, J. Myocardial alternative RNA splicing and gene expression profiling in early stage hypoplastic left heart syndrome. *PLoS ONE* **2012**, *7*, e29784. [[CrossRef](#)] [[PubMed](#)]
75. Nagasawa, C.K.; Kibiryeveva, N.; Marshall, J.E.; Bittel, D.C. scaRNA1 Levels Alter Pseudouridylation in Spliceosomal RNA U2 Affecting Alternative mRNA Splicing and Embryonic Development. *Pediatr. Cardiol.* **2020**, *41*, 341–349. [[CrossRef](#)] [[PubMed](#)]
76. Farazi, T.A.; Leonhardt, C.S.; Mukherjee, N.; Mihailovic, A.; Li, S.; Max, K.E.; Meyer, C.; Yamaji, M.; Cekan, P.; Jacobs, N.C.; et al. Identification of the RNA recognition element of the RBPMS family of RNA-binding proteins and their transcriptome-wide mRNA targets. *RNA* **2014**, *20*, 1090–1102. [[CrossRef](#)] [[PubMed](#)]
77. Pizzuti, A.; Novelli, G.; Ratti, A.; Amati, F.; Bordoni, R.; Mandich, P.; Bellone, E.; Conti, E.; Bengala, M.; Mari, A.; et al. Isolation and characterization of a novel transcript embedded within HIRA, a gene deleted in DiGeorge syndrome. *Mol. Genet. Metab.* **1999**, *67*, 227–235. [[CrossRef](#)]
78. Wang, Y.; Gogol-Döring, A.; Hu, H.; Fröhler, S.; Ma, Y.; Jens, M.; Maaskola, J. Integrative analysis revealed the molecular mechanism underlying RBM10-mediated splicing regulation. *EMBO Mol. Med.* **2013**, *5*, 1431–1442. [[CrossRef](#)] [[PubMed](#)]
79. Tessier, S.J.; Loïselle, J.J.; McBain, A.; Pullen, C.; Koenderink, B.W.; Roy, J.G.; Sutherland, L.C. Insight into the role of alternative splicing within the RBM10v1 exon 10 tandem donor site. *BMC Res. Notes* **2015**, *8*, 46. [[CrossRef](#)]
80. Johnston, J.J.; Teer, J.K.; Cherukuri, P.F.; Hansen, N.F.; Loftus, S.K.; NIH Intramural Sequencing Center (NISC); Chong, K.; Mullikin, J.C.; Biesecker, L.G. Massively Parallel Sequencing of Exons on the X Chromosome Identifies RBM10 as the Gene that Causes a Syndromic Form of Cleft Palate. *Am. J. Hum. Genet.* **2010**, *86*, 743–748. [[CrossRef](#)]
81. Morris, S.A.; Ethen, M.K.; Penny, D.J.; Canfield, M.A.; Minard, C.G.; Fixler, D.E.; Nembhard, W.N. Prenatal diagnosis, birth location, surgical center, and neonatal mortality in infants with hypoplastic left heart syndrome. *Circulation* **2014**, *129*, 285–292. [[CrossRef](#)] [[PubMed](#)]
82. Beqqali, A.; Bollen, I.A.; Rasmussen, T.B.; van den Hoogenhof, M.M.; van Deutekom, H.W.; Schafer, S.; Haas, J.; Meder, B.; Sørensen, K.E.; van Oort, R.J.; et al. A mutation in the glutamate-rich region of RNA-binding motif protein 20 causes dilated cardiomyopathy through missplicing of titin and impaired Frank-Starling mechanism. *Cardiovasc Res.* **2016**, *112*, 452–463. [[CrossRef](#)]
83. Fan, C.; Chen, Q.; Wang, Q.K. Functional role of transcriptional factor TBX5 in pre-mRNA splicing and Holt-Oram syndrome via association with SC35. *J. Biol. Chem.* **2009**, *284*, 25653–25663. [[CrossRef](#)] [[PubMed](#)]
84. Bose, D.; Vaigundan, D.; Shetty, M.; Krishnappa, J.; Kutty, A.V.M. Identification of intronic-splice site mutations in GATA4 gene in Indian patients with congenital heart disease. *Mutat. Res.* **2017**, *803–805*, 26–34. [[CrossRef](#)] [[PubMed](#)]
85. Li, X.; Shi, L.; Xu, M.; Zheng, X.; Yu, Y.; Jin, J. RCAN1 Mutation and Functional Characterization in Children with Sporadic Congenital Heart Disease. *Pediatr. Cardiol.* **2018**, *39*, 226–235. [[CrossRef](#)]

86. Fusco, C.; Morlino, S.; Micale, L.; Ferraris, A.; Grammatico, P.; Castori, M. Characterization of Two Novel Intronic Variants Affecting Splicing in FBN1-Related Disorders. *Genes* **2019**, *10*, 442. [[CrossRef](#)]
87. Gong, Q.; Stump, M.R.; Deng, V.; Zhang, L.; Zhou, Z. Identification of Kv11.1 isoform switch as a novel pathogenic mechanism of long-QT syndrome. *Circ. Cardiovasc. Genet.* **2014**, *7*, 482–490. [[CrossRef](#)]
88. Awad, M.M.; Dalal, D.; Tichnell, C.; James, C.; Tucker, A.; Abraham, T.; Spevak, P.J.; Calkins, H.; Judge, D.P. Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2. *Hum. Mutat.* **2006**, *27*, 1157. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.